Fennec Pharmaceuticals Inc.
Moat Score — Fennec Pharmaceuticals Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | PEDMARK is protected by Orange Book patents running to 2039, U.S. orphan drug exclusivity to 2029, and EU pediatric exclusivity to 2033, plus a March 2026 Cipla settlement blocking generic entry until September 2033 - a genuinely layered legal moat for a single-product company. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Fennec is a virtual manufacturer with no owned plants, so it has no structural cost advantage, and compounded sodium thiosulfate is a materially cheaper unapproved alternative. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | As the only FDA/EMA-approved agent for cisplatin-induced ototoxicity, Fennec commands real pricing power with oncology centers and payers, tempered by the ever-present substitution threat from compounded versions of the same molecule. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | PEDMARK is a pharmaceutical product with no network effects between prescribers or patients. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a pediatric oncology center adopts PEDMARK into its chemotherapy protocol there is some clinical and formulary inertia, but compounding pharmacies offer a continuous, low-friction substitution path that caps true switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The addressable patient population (roughly 2,157 U.S. and 1,250 European cisplatin-treated pediatric patients per year) is small enough to discourage large pharma competitors from entering, a natural but not absolute barrier given the compounding workaround. |